Hundreds of School Districts Have Been Ignoring Desegregation Orders for Decades
The federal government’s vigilance in enforcing the court-backed desegregation of the country’s schools is a shadow of what it once was.
Browsing Tag
ProPublica
214 posts
The War on Cancer: Big Pharma Is Keeping Us From Developing Low-Cost Treatments
Big Pharma’s focus on blockbuster cancer drugs squeezes out research into potential treatments that are more affordable. Says one researcher: "What is scientific and sexy is driven by what can be monetized."
IRS Does Nothing After Political Dark Money Group Blatantly Ignores the Law
The Government Integrity Fund spent most of its money on election ads, despite IRS rules prohibiting a social welfare non-profit from doing so.
3 Problems With Obama’s New Clemency Initiative
Prisoners’ advocates call the reforms a step forward, but they don’t address discrimination in presidential pardons or apply to everyone serving harsh sentences from outdated guidelines.
Meet the Doctor Who Gave $1 Million of His Own Money to Keep His Gun Research Going
Since Congress pressured the CDC to stop funding research on gun violence, Dr. Garen Wintemute has donated more than $1.1 million of his own money to keep his research going.
Even After Doctors Are Sanctioned or Arrested, Medicare Keeps Paying
An analysis of recently released data shows that dozens of physicians who received payments from Medicare in 2012 had been kicked out of Medicaid, charged with fraud, or settled claims of overbilling Medicare itself.
The Big Revamp of the Pentagon’s Troubled Mission to Find Missing Soldiers Looks a Lot Like the Old Revamp
Without change of leadership throughout, meaningful improvement could be elusive.
The U.S. Needs to Stop Running Internet Security Like a Wikipedia Volunteer Project
One lesson of the Heartbleed bug is that our government is paying to undermine Internet security, not to fix it.
IPO Gives Us a Look Inside Sina Weibo, a Company Struggling With Censorship
Weibo, “China’s Twitter,” started offering shares on NASDAQ last week. Its regulatory disclosures reveal a company’s balancing act between censoring too much and too little.